High efficacy and biocompatibility: Application and biological evaluation of LA67 liposome in colon cancer therapy.

In this study, a single-component liposomal nano-delivery system (LA67@Lipo) was developed for the new antitumor drug LA67. The resulting liposomes were homogenous, spherical vesicles with an average particle size of approximately 109.2 ± 3.8 nm, polydispersity index value of 0.147, and zeta potential of -8.78 ± 0.29 mV, demonstrating excellent dispersibility and stability. The drug encapsulation efficiency surpassed 89.7 ± 3.5 %. Liposomes exhibited a sustained in vitro drug release profile. LA67@Lipo markedly improved internalization by C26 colon cancer cells, effectively inhibiting cell proliferation and inducing apoptosis. In a C26 tumor-bearing mouse model, intravenously administered LA67@Lipo exhibited superior tumor suppression effects. It inhibited Ki-67 and CD31 and decreased intratumoral microvessel density without inducing systemic toxicity, demonstrating excellent in vivo antitumor efficacy and good biosafety. In conclusion, LA67@Lipo is an efficacious therapeutic approach for colon cancer. This optimized design of LA67@Lipo meets clinical demand for "safety, efficacy, and manufacturability" while addressing batch-to-batch reproducibility in nanomedicine.